# US 2020/0368174 A1 · Particles for targeted delivery of active agents into adipose stromal cells

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0368174 A1
- Document ID: US20200368174A1
- Status: Published application
- Kind: A1
- Application number: 16/966,310
- Filed: 2019-02-21
- Published: 2020-11-26
- Earliest claimed: 2018-02-21
- Assignees: Texas Tech University System; University of Tennessee Research Foundation
- Applicants: Texas Tech University System; University of Tennessee research Foundation
- Inventors: Shu Wang; Ling Zhao; Zhaoyang Fan; Yujiao Zu
- Web page: https://patentgrep.com/patent/US20200368174A1

## CPC

- A61K 9/5123: {Organic compounds, e.g. fats, sugars}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/6911: {the form being a liposome}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Embodiments of the present disclosure pertain to delivery agents for delivering one or more active agents to desired cells (e.g., adipose stromal cells). The delivery agents generally include: (1) a particle; (2) one or more active agents carried by the particle; and (3) a targeting agent associated with the particle, where the targeting agent directs the delivery agent to the desired cells. Additional embodiments of the present disclosure pertain to methods for delivering active agents to adipose stromal cells through the use of the aforementioned delivery agents. In some embodiments, the methods include a step of associating the adipose stromal cells with the delivery agent such that the associating results in the delivery of the active agents into the adipose stromal cells. The associating can occur by administering the delivery agent to a subject for the treatment or prevention of obesity and related disorder or diseases in the subject.

## Claims

### Claim 1

A method for delivering one or more active agents to adipose stromal cells through the use of a delivery agent, said method comprising:
associating the adipose stromal cells with the delivery agent, wherein the delivery agent comprises:
a particle,
one or more active agents carried by the particle, and
a targeting agent associated with the particle,
wherein the targeting agent directs the delivery agent to the adipose stromal cells; and
wherein the associating results in the delivery of the one or more active agents into the adipose stromal cells.

### Claim 2 (depends on 1)

The method of claim 1, wherein the particle is a lipid-based particle comprising a phospholipid.

### Claim 3

(canceled)

### Claim 4 (depends on 1)

The method of claim 1, wherein the particle lacks triglycerides.

### Claim 5 (depends on 1)

The method of claim 1, wherein the particle contains triglycerides.

### Claim 6 (depends on 1)

The method of claim 1, wherein the particle further comprises an active agent stabilizer or an excipient,
wherein active agent stabilizer or excipient is co-incorporated with the one or more active agents within the particle, and
wherein the active agent stabilizer or excipient is selected from the group consisting of an antioxidant, vitamin E, vitamin C, vitamin A, triglyceride, uric acid, glutathione, triglycerides, monosaccharides, disaccharides, polysaccharides, fibers, lipids, vitamins, minerals, phytochemicals, proteins, terpenoids, or combinations thereof.

### Claim at position 7

7-11. (canceled)

### Claim 12 (depends on 1)

The method of claim 1, wherein the particle further comprises a surfactant on a surface of the particle.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method of claim 1, wherein the particle comprises a surface with a negative charge.

### Claim 15 (depends on 1)

The method of claim 1, wherein the particle is in the form of nanoparticles, wherein the nanoparticles comprise diameters ranging from about 20 nm to about 200 nm.

### Claim 16

(canceled)

### Claim 17 (depends on 1)

The method of claim 1,
wherein the particle comprises a hydrophobic core, and
wherein the one or more active agents comprise hydrophobic active agents that are within the hydrophobic core.

### Claim at position 14

18-19. (canceled)

### Claim 20 (depends on 1)

The method of claim 1, wherein the one or more active agents are dispersed within the particle in the form of an amorphous phase.

### Claim 21 (depends on 1)

The method of claim 1, wherein the one or more active agents are selected from the group consisting of small molecules, peptides, polypeptides, proteins, hydrophobic active agents, hydrophilic active agents, drugs, nucleotides, RNA, shRNA, siRNA, miRNA, DNA, nutrients, phytochemicals, and combinations thereof.

### Claim 22 (depends on 1)

The method of claim 1, wherein the one or more active agents have a concentration of more than 1 nM or more than 1 LM.

### Claim 23

(canceled)

### Claim 24 (depends on 1)

The method of claim 1, wherein the one or more active agents comprise resveratrol.

### Claim 25 (depends on 1)

The method of claim 1, wherein the one or more active agents are encapsulated within the particle.

### Claim 26 (depends on 1)

The method of claim 1, wherein the targeting agent is selected from the group consisting of amino acids, peptides, proteins, aptamers, antibodies, small molecules, carbohydrates, polysaccharides, lipids, and combinations thereof.

### Claim 27 (depends on 1)

The method of claim 1, wherein the targeting agent is associated with en a surface of the particle through a linker, wherein the linker is covalently coupled to a surface of the particle and to the targeting agent.

### Claim 28

(canceled)

### Claim 29 (depends on 27)

The method of claim 27, wherein the linker comprises polyethylene glycol.

### Claim 30 (depends on 1)

The method of claim 1,
wherein the targeting agent targets an epitope on the adipose stromal cells,
wherein the epitope is a receptor on adipose stromal cells, and
wherein the delivery of the one or more active agents into the adipose stromal cells occurs by receptor-mediated endocytosis.

### Claim 31 (depends on 30)

The method of claim 30, wherein the epitope is a cleavage product of decorin

### Claim 32

(canceled)

### Claim 33 (depends on 1)

The method of claim 1, wherein the targeting agent comprises a peptide selected from the group consisting of CSWKYWFGEC (WAT 7) (SEQ ID NO: 1), GSWKYWFGEGGC (SEQ ID NO: 2), and combinations thereof.

### Claim 34

(canceled)

### Claim 35 (depends on 1)

The method of claim 1,
wherein the adipose stromal cells are selected from the group consisting of adipose stromal stem cells, adipose stromal progenitor cells, and combinations thereof, and
wherein the adipose stromal cells are a component of a white adipose tissue, a brown adipose tissue, a beige adipose tissue, and combinations thereof.

### Claim 36

(canceled)

### Claim 37 (depends on 1)

The method of claim 1, wherein the associating occurs in vitro.

### Claim 38 (depends on 1)

The method of claim 1,
wherein the associating occurs in vivo in a subject,
wherein the associating comprises administering the delivery agent to the subject,
wherein the delivery agent is used to treat or prevent a disorder or disease in the subject, and
wherein the disorder or disease is selected from the group consisting of metabolic syndromes, diabetes, type 2 diabetes, cardiovascular diseases, hypertension, coronary heart diseases, insulin resistance, dyslipidemia, cancer, osteoarthritis, rheumatoid arthritis, aging, wrinkles, alopecia, liver failure, multiple sclerosis, obesity, and combinations thereof.

### Claim at position 34

39-40. (canceled)

### Claim 41 (depends on 38)

The method of claim 38,
wherein the delivery agent is used to treat or prevent obesity in the subject, and
wherein the delivery agent treats or prevents obesity by conversion of white adipose tissue to brown adipose tissue, beige adipose tissue, brown-like adipose tissue, or combinations thereof in the subject.

### Claim 42

(canceled)

### Claim 43 (depends on 1)

The method of claim 1, wherein the delivery agent is embedded within hydrogels.

### Claim at position 38

44-81. (canceled)
